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points was reported by 76.1% of alcaftadinetreated subjects compared with 58.1% of olopatadine-treated subjects (P = 0.0121).
Treatment with alcaftadine 0.25% and olopatadine 0.2% was safe and well tolerated; no serious adverse events were reported. [6] .
Conclusion
Ocular itching, the hallmark symptom of allergic conjunctivitis, is often accompanied by tearing, conjunctival redness, eyelid swelling, and chemosis [7] . Allergic conjunctivitis is mediated by immunoglobulin E-activated degranulation of mast cells and the release of a cascade of inflammatory mediators, including histamine, in response to allergens [8, 9] .
Histamine release and activation of histamine H 1 receptors in the conjunctiva leads to ocular itching, while stimulation of H 2 receptors on the ocular surface results in vasodilation and is associated with ocular redness, eyelid swelling, and chemosis [10, 11] . Recent evidence suggests that histamine binding to and activation of H 4 receptors also play a role in allergic conjunctivitis [12, 13] . Topical ophthalmic antihistamines are the primary treatment options for allergic conjunctivitis. Currently, alcaftadine 0.25% and olopatadine 0.2% are the only approved once-daily ophthalmic solutions for allergic conjunctivitis in the United States [14] [15] [16] [17] [18] [19] . Both olopatadine and alcaftadine are classified as dual-action antiallergic agents, directly inhibiting histamine receptor activation and indirectly reducing allergic responses by stabilizing mast cells [20] .
Clinical studies evaluating alcaftadine and olopatadine as treatment options for allergic conjunctivitis have used the conjunctival allergen challenge (CAC) model to assess clinical efficacy [21, 22] 
METHODS

Study Design
Two multicenter, double-masked, randomized activeand placebo-controlled trials 
Study Eligibility Criteria
Subject eligibility was identical for both studies.
Key inclusion criteria included subjects with a history of ocular allergies and at least one positive skin test within 24 months of the trial start date to one of the following: cat dander, grasses, ragweed, dog dander, cockroach, dust mites, and trees; a best-corrected visual acuity potential for randomization into a treatment arm with a pregnancy category C therapeutic [19] , women who were pregnant or planning a pregnancy, lactating, or of child-bearing age and not using a medically acceptable form of birth control for the entire period of the trials were excluded. Subjects planning surgical procedures during the trial period or those with a history of retinal detachment, diabetic retinopathy, or progressive retinal disease also were ineligible.
Treatment and Assessments
Assessments from the three identical subject visits of both studies were included in the pooled analysis. At the first study visit (day -21 ± 3) or titration visit, allergens were instilled in each eye followed by the subject rating ocular itching severity at 10 min. Allergen concentrations were increased serially until the scores for both itching and conjunctival redness reached C2.0. The maximal allergen concentration used during this titration visit was utilized for all subsequent visits. Itching severity was graded using a five-point scale (0-4), which allowed for half measures [15, 17, 21, [23] [24] [25] [26] . Conjunctival redness was scored by the investigator using a five-point ocular redness scale (0-4) [15, 17, 21, [23] [24] [25] [26] . At the second study visit (day -14 ± 3) or confirmation visit, allergen challenge using the final concentration from the first visit was performed to provide baseline data for those subjects who continued to satisfy eligibility criteria. Subjects rated ocular itching at 3, 5, and 7 min after allergen instillation. Subjects who met the qualifying criteria of postchallenge bilateral itching C2 and who also had bilateral conjunctival redness C2 at two of the three time points (7, 15, and 20 min) continued to visit 3A approximately 2 weeks after visit 2.
At visit 3A (day 0), subjects were randomized in a 1 16 ? 1 h after study drug instillation in both eyes using the same allergen and dose that had elicited a positive reaction at visits 1 and 2. The first study also had a fourth visit that was used to assess duration of action at 24 h posttreatment instillation.
Efficacy and Safety Parameters
The primary efficacy endpoint was ocular itching quantified by the subject at 3 min post-CAC. Secondary efficacy endpoints included ocular itching evaluated by the subject at 5 and 7 min post-CAC. Safety was assessed by monitoring adverse events (elicited and observed) throughout the studies, which were then coded to system organ class and preferred terms using the Medical Dictionary for Regulatory Activities (MedDRA) version 13.1
[29].
Data Analysis and Statistical Methods
Both eyes of each subject were used for statistical summaries and analyses. Categorical variables were summarized using frequencies and percentages, and continuous variables were summarized using descriptive statistics, including the number of observations, mean, standard deviation, median, minimum, and maximum values. Hypothesis testing, unless otherwise indicated, was performed at the 5% significance level of type I error for two-sided tests. The last observation carried forward method was used to handle missing and incomplete efficacy data for the primary measure. All secondary efficacy measures were analyzed using observed data only.
The intent-to-treat population, comprised of all subjects who were randomized, was used for the efficacy analyses. A subset of the intent-totreat population, consisting of subjects who completed the study with no protocol violations, formed the per-protocol population. This population was analyzed as treated using observed data only and was used for confirmatory analyses. The safety population included all randomized subjects who received at least one dose of the study treatment.
The primary efficacy measure was summarized by visit, time point, and treatment group using descriptive statistics.
The differences in the means between treatment groups were calculated, and mean ocular itching scores for each of the treatments were compared using two-sample t tests. In addition, the nonparametric Wilcoxon rank- 
RESULTS
Subject Demographics and Characteristics
A total of 284 subjects were enrolled in the two clinical studies following screening visits 1 and 2; 96 subjects were randomized to receive alcaftadine 0.25% ophthalmic solution, 95 received olopatadine 0.2% ophthalmic solution, and 93 received placebo. Thirteen of the 284 randomized subjects (alcaftadine 0.25%, n = 6; olopatadine 0.2%, n = 5; placebo, n = 2) did not complete the studies. The most common reasons for treatment discontinuation across treatment arms were loss to follow-up and adverse events (Fig. 1) .
Subject demographics were well balanced among the three treatment groups with no significant differences with regard to age, gender, or race, while iris color differed significantly among groups (Table 1) . Table 2 ).
Efficacy Outcome Measures
Alcaftadine 0.25%-treated subjects consistently demonstrated greater percentage reduction in itching from baseline at 3, 5, and 7 min post-CAC (-81.0%, -74.1%, and -70.6%, respectively) compared with olopatadine 0.2%-treated subjects (-63.2%, -65.7%, and -65.2%, respectively). For both actives, the percentage reduction in itching from baseline was superior over placebo at 3, 5, and 7 min (-23.7%, -24.1%, and -30.2%, respectively).
The ocular itching primary efficacy measure was further assessed by comparing the proportion of subjects in each group with minimal itch (itch score \1) and zero itch (itch score = 0). For subjects who met the criteria for minimal itch or zero itch at all three time points (3, 5, and 7 min), significantly higher proportions of subjects achieved overall minimal itch and zero itch in the alcaftadine 0.25% and olopatadine 0.2% groups compared with the placebo group (minimal itch, P\0.0001; zero itch, P B 0.0006, for both actives versus placebo; Fig. 4) . A significantly greater proportion of alcaftadine 0.25%-treated subjects achieved an itch score \1 compared with olopatadine 0.2%-treated subjects over all time points (76.1% vs. 58.1%; P = 0.0121); no significant differences were observed in the proportion of subjects achieving zero itch (Fig. 5a) . A significantly larger proportion of subjects who received treatment with 
Max maximum, Min minimum, SD standard deviation * Analysis of variance, Fisher's exact test a Percentages are based on the total number of subjects in each treatment group except for iris color, which is based on the total number of eyes in each treatment group alcaftadine 0.25% and olopatadine 0.2% reported lower itch scores between 0 and 1.0 post-CAC compared with placebo-treated subjects 16 h post-treatment instillation. A greater leftward shift was observed in the alcaftadine group than in the olopatadine group; more subjects receiving alcaftadine 0.25% reported itch scores of 0 and 0.5 (Fig. 5b) .
Safety
Sixteen adverse events were reported among 283 subjects comprising the safety population. A total of 11 (3.9%) subjects, four treated with alcaftadine 0.25%, five treated with olopatadine 0.2%, and two receiving placebo experienced at least one adverse event. No adverse events were considered to be related to study treatment, and no serious adverse events were reported during the course of the studies. In the pooled analysis, alcaftadine 0.25%-treated subjects experienced significantly lower mean ocular itch scores than olopatadine 0.2%-treated subjects at 3 min post-CAC (P = 0.0006). Fig. 2 Comparison of mean itch scores at baseline and 16 h after treatment instillation at 3 min post-conjunctival allergen challenge (primary endpoint). Mean itch scores for alcaftadine 0.25%, olopatadine 0.2%, and placebo. *P\0.0001 for alcaftadine and olopatadine versus placebo; **P = 0.0006 for alcaftadine versus olopatadine. P values calculated using the two-sample t test Fig. 3 Comparison of overall mean itch scores at baseline and 16 h after treatment instillation over all time points (3, 5, and 7 min) post-conjunctival allergen challenge. Mean itch scores for alcaftadine 0.25%, olopatadine 0.2%, and placebo. *P\0.0001 for alcaftadine and olopatadine versus placebo; **P = 0.0390 for alcaftadine versus olopatadine. P values calculated using the repeated measures analysis of covariance model accounting for treatment and time points
In addition, alcaftadine 0.25% ophthalmic solution also was superior to olopatadine 0.2% ophthalmic solution in reducing mean itch scores over all time points measured (3, 5, and 7 min; P = 0.0390). A significantly greater proportion of alcaftadine 0.25%-treated subjects achieved minimal itch (itch score \1) compared with olopatadine 0.2%-treated subjects over all time points (P = 0.0121).
There were no statistically significant differences in the proportion of subjects with zero itch (itch score = 0). Both alcaftadine and olopatadine were superior to placebo at relieving ocular itch associated with allergic conjunctivitis in the pooled analysis.
Alcaftadine is unique among ocular antihistamines in that it exhibits antagonistic activity against H 1 , H 2 , and H 4 receptors (although with lower affinity than H 1 and H 2 ) [20, 30] . The role of H 4 receptors in allergic conjunctivitis has not been fully elucidated; in vitro studies suggest that histamine binding to H 4 receptors mediates eosinophil chemotaxis [31] . In this pooled analysis, the distribution of subject-reported itch scores at 16 h posttreatment instillation over all time points showed an improvement with alcaftadine 0.25% relative to olopatadine in the degree of relief and the proportion of subjects whose symptoms are alleviated following allergen challenge, achieving a statistically significant greater percentage of subjects with scores of 0 or 0.5 relative to olopatadine 0.2% on a five-point scale. In addition to this greater magnitude of effect, in a previous study, alcaftadine 0.25% had a rapid onset of action as measured at 15 min post-treatment instillation, which was superior to that of olopatadine 0.1%, and sustained duration of action up to 16 h post- CAC conjunctival allergen challenge * P values calculated using two-sample t test. P values calculated using repeated measures analysis of covariance model accounting for treatment and time Fig. 4 Comparison of overall percentage of subjects with minimal itch and zero itch scores at 16 h after treatment instillation. Percentage of subjects with minimal itch (itch score \1) and zero itch for alcaftadine 0.25%, olopatadine 0.2%, and placebo at all time points post-conjunctival allergen challenge. Subjects had to meet the itch score criteria (\1 or 0) at 3, 5, and 7 min post-conjunctival allergen challenge. *P\0.0001 for alcaftadine and olopatadine versus placebo; **P B 0.0006 for alcaftadine and olopatadine versus placebo; ***P = 0.0121 for alcaftadine versus olopatadine. P values calculated using Fisher's exact test treatment instillation [14] . In a murine model of allergic conjunctivitis, alcaftadine demonstrated a greater effect than olopatadine on eosinophil recruitment and stability of the epithelial junctional protein, zonula occludens-1 [32] . Overall, these in vivo results suggest that differences observed clinically between alcaftadine and olopatadine may reflect a greater ability of alcaftadine to prevent allergen-activated disruption of the epithelial barriers [33] .
Similar to other reports of alcaftadine and olopatadine [14, 15, 17, 26] , treatment with alcaftadine 0.25% and olopatadine 0.2% was found to be generally well tolerated. While eleven (3.9%) subjects experienced at least one adverse event, none of the adverse events were related to study treatment. In addition, there were no serious adverse events reported at any time during either study. 
